Your browser doesn't support javascript.
loading
Assessing the effectiveness of AS-48 in experimental mice models of Chagas' disease.
Martín-Escolano, Rubén; Cebrián, Rubén; Maqueda, Mercedes; Romero, Desirée; Rosales, Maria José; Sánchez-Moreno, Manuel; Marín, Clotilde.
Afiliación
  • Martín-Escolano R; Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, E-18071 Granada, Spain.
  • Cebrián R; Department of Microbiology, Faculty of Sciences, Avda. Fuentenueva s/n, University of Granada, 18071 Granada, Spain.
  • Maqueda M; Department of Microbiology, Faculty of Sciences, Avda. Fuentenueva s/n, University of Granada, 18071 Granada, Spain.
  • Romero D; Department of Statistics and Operations Research, Faculty of Sciences, Avda. Fuentenueva s/n, University of Granada, 18071 Granada, Spain.
  • Rosales MJ; Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, E-18071 Granada, Spain.
  • Sánchez-Moreno M; Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, E-18071 Granada, Spain.
  • Marín C; Department of Parasitology, Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada, Severo Ochoa s/n, E-18071 Granada, Spain.
J Antimicrob Chemother ; 75(6): 1537-1545, 2020 06 01.
Article en En | MEDLINE | ID: mdl-32129856
OBJECTIVES: We report the in vivo trypanocidal activity of the bacteriocin AS-48 (lacking toxicity), which is produced by Enterococcus faecalis, against the flagellated protozoan Trypanosoma cruzi, the aetiological agent of Chagas' disease. METHODS: We determined the in vivo activity of AS-48 against the T. cruzi Arequipa strain in BALB/c mice (in both acute and chronic phases of Chagas' disease). We evaluated the parasitaemia, the reactivation of parasitaemia after immunosuppression and the nested parasites in the chronic phase by PCR in target tissues. RESULTS: AS-48 reduced the parasitaemia profile in acute infection and showed a noteworthy reduction in the parasitic load in chronic infection after immunosuppression according to the results obtained by PCR (double-checking to demonstrate cure). CONCLUSIONS: AS-48 is a promising alternative that provides a step forward in the development of a new therapy against Chagas' disease.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trypanosoma cruzi / Enfermedad de Chagas Idioma: En Revista: J Antimicrob Chemother Año: 2020 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trypanosoma cruzi / Enfermedad de Chagas Idioma: En Revista: J Antimicrob Chemother Año: 2020 Tipo del documento: Article